RDY vs. MRNA, TAK, TEVA, BGNE, CTLT, QGEN, PCVX, ROIV, LNTH, and RVMD
Should you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include Moderna (MRNA), Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Catalent (CTLT), Qiagen (QGEN), Vaxcyte (PCVX), Roivant Sciences (ROIV), Lantheus (LNTH), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.
Moderna (NASDAQ:MRNA) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, community ranking, institutional ownership, earnings, valuation and dividends.
Dr. Reddy's Laboratories has a net margin of 19.97% compared to Dr. Reddy's Laboratories' net margin of -115.82%. Moderna's return on equity of 21.32% beat Dr. Reddy's Laboratories' return on equity.
Dr. Reddy's Laboratories received 117 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 59.25% of users gave Dr. Reddy's Laboratories an outperform vote while only 57.47% of users gave Moderna an outperform vote.
Dr. Reddy's Laboratories has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.
Moderna presently has a consensus price target of $133.88, indicating a potential upside of 9.63%. Dr. Reddy's Laboratories has a consensus price target of $81.00, indicating a potential downside of 0.27%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Moderna is more favorable than Dr. Reddy's Laboratories.
In the previous week, Moderna had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 21 mentions for Moderna and 20 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.41 beat Moderna's score of 0.01 indicating that Moderna is being referred to more favorably in the media.
Moderna has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.
75.3% of Moderna shares are held by institutional investors. Comparatively, 14.0% of Dr. Reddy's Laboratories shares are held by institutional investors. 15.7% of Moderna shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Moderna and Dr. Reddy's Laboratories tied by winning 9 of the 18 factors compared between the two stocks.
Get Dr. Reddy's Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dr. Reddy's Laboratories Competitors List
Related Companies and Tools
